SRR819946
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR607406 | GTEX | — | 0.970 |
| 2 | SRR1330699 | GTEX | — | 0.942 |
| 3 | SRR1375203 | GTEX | — | 0.940 |
| 4 | SRR607647 | GTEX | — | 0.935 |
| 5 | SRR1366961 | GTEX | — | 0.932 |
| 6 | SRR1374115 | GTEX | — | 0.930 |
| 7 | SRR607935 | GTEX | — | 0.926 |
| 8 | SRR607478 | GTEX | — | 0.918 |
| 9 | SRR1455698 | GTEX | — | 0.916 |
| 10 | SRR8943034 | — | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.409 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.388 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.373 | Remibrutinib | — uncovered |
| COAGULATION | 0.358 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.331 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.322 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.265 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.250 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.247 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.238 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.237 | Inavolisib | — uncovered |
| MYOGENESIS | 0.217 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.216 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.197 | Idelalisib | — uncovered |
| COMPLEMENT | 0.188 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.175 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.166 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.138 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.105 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.082 | Inavolisib | — uncovered |